Ribosomal Protein S6 Kinases, 70-kDa
"Ribosomal Protein S6 Kinases, 70-kDa" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of ribosomal protein S6 kinases that are considered the major physiological kinases for RIBOSOMAL PROTEIN S6. Unlike RIBOSOMAL PROTEIN S6 KINASES, 90KDa the proteins in this family are sensitive to the inhibitory effects of RAPAMYCIN and contain a single kinase domain. They are referred to as 70kDa proteins, however ALTERNATIVE SPLICING of mRNAs for proteins in this class also results in 85kDa variants being formed.
| Descriptor ID |
D038762
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.862.249 D12.644.360.600.249 D12.776.476.600.249
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ribosomal Protein S6 Kinases, 70-kDa".
Below are MeSH descriptors whose meaning is more specific than "Ribosomal Protein S6 Kinases, 70-kDa".
This graph shows the total number of publications written about "Ribosomal Protein S6 Kinases, 70-kDa" by people in this website by year, and whether "Ribosomal Protein S6 Kinases, 70-kDa" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ribosomal Protein S6 Kinases, 70-kDa" by people in Profiles.
-
Inhibition of p70 S6 kinase (S6K1) activity by A77 1726 and its effect on cell proliferation and cell cycle progress. Neoplasia. 2014 Oct; 16(10):824-34.
-
Cellular effects of everolimus and sirolimus on podocytes. PLoS One. 2013; 8(11):e80340.
-
Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation. Cancer Res. 2013 Jun 01; 73(11):3248-61.
-
Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors. J Med Chem. 2012 Jun 14; 55(11):5291-310.